Feed BNR
BN

Burning Rock Biotech Limited BNR · NASDAQ

$12.90 -17.31% (-$2.70)

Market cap
¥110.2M
Enterprise value
-¥264.0M
P/E
-
Forward P/E
-
PEG
-
P/S
0.2x
P/FCF
-
EV/EBITDA
-
ROIC
-12.0%
Gross margin
74.6%
Net margin
-13.6%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.30
Free float
83.1%

About the company

Burning Rock Biotech Limited (BNR) is a biotechnology company focused on the development and commercialization of diagnostic tests for oncological diseases. Their products include genetic tests and tests for the detection of tumor biomarkers, which help physicians accurately diagnose and treat cancer. Burning Rock Biotech is known for its ability to integrate advanced technologies such as DNA sequencing and artificial intelligence into its diagnostic tests, enabling rapid and precise diagnosis of cancerous diseases. The company also focuses on developing personalized treatment approaches that improve treatment outcomes for cancer patients. Burning Rock Biotech Limited (BNR) shares could be suitable for investors looking for opportunities in the biotechnology sector with an emphasis on cancer diagnosis and treatment.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Yusheng Han

Employees

667

Headquarters

Guangzhou

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.